Symbio Of Japan Obtains Clinical Study Rights From Cephalon Affiliate
This article was originally published in PharmAsia News
Tokyo-based Symbio obtained the rights to commence Japanese domestic clinic trials for Lupuzor for systemic lupus erythematosus from the Swiss affiliate of U.S.-based Cephalon
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.